睿知中国疾病研究地图
候选清单0

正在招募胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属中山医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07213791,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Must have histologically or cytologically confirmed diagnosis of one of the following:

    入选标准第 2 条

  3. Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.

    入选标准第 15 条

    HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.

    入选标准第 16 条

    HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).

    入选标准第 17 条

    TNBC: Participants must have received at least 1 prior line of therapy for metastatic disease, and must have received an ADC unless unavailable, ineligible, or refused.

    入选标准第 18 条

    Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.

    入选标准第 19 条

    Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.

    入选标准第 23 条

  4. Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.

    入选标准第 24 条

  5. Measured creatinine clearance ≥60 milliliters per minute (mL/min)

    入选标准第 25 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07213791,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
  2. Must have histologically or cytologically confirmed diagnosis of one of the following:
  3. Adenocarcinoma of the pancreas
  4. Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer
  5. HER2-positive breast cancer
  6. Triple negative breast cancer (TNBC)
  7. Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)
  8. Gastric cancer (adenocarcinoma)
  9. Colorectal cancer (CRC)
  10. Esophageal cancer (squamous cell carcinoma or adenocarcinoma)
  11. Cholangiocarcinoma
  12. Other non- central nervous system (CNS) solid tumors, which have demonstrated FAP uptake via positron emission tomography (PET),
  13. Must have received prior treatments as indicated below:
  14. Phase 1a
  15. Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.
  16. HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.
  17. HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).
  18. TNBC: Participants must have received at least 1 prior line of therapy for metastatic disease, and must have received an ADC unless unavailable, ineligible, or refused.
  19. Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.
  20. Gastric cancer, CRC, esophageal cancer (squamous cell carcinoma or adenocarcinoma), and cholangiocarcinoma: Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; this may include, but does not require, prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.
  21. Other non-CNS solid tumors: Participants must have exhausted, be ineligible for, or refused all standard-of-care therapy appropriate for their disease.
  22. Phase 1b:
  23. Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.
  24. Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
  25. Measured creatinine clearance ≥60 milliliters per minute (mL/min)

排除标准:Exclusion Criteria:

  1. Have known active central nervous system (CNS) metastases or carcinomatous meningitis.
  2. Have significant cardiovascular disease
  3. Have prolongation of the corrected QTcF >470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
  4. Have evidence of ongoing and untreated urinary tract obstruction
  5. Had previous hemi- or total-body radiation.
  6. Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T therapy, T-cell receptor [TCR] therapy, etc.)
  7. Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

引自 ClinicalTrials.gov, NCT07213791, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07213791,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07213791